1. Home
  2. Directory
  3. Nebraska
  4. Grand Island
  5. Optometrist
  6. NPI Profile
  7. Prescriptions 1811034713

DR. TAMARA LYNN BONNES-HEIL O.D.
Prescription History 1811034713
Optometrist in Grand Island, NE

NPI Status: Active since January 31, 2007

Contact Information

724 N DIERS AVE
GRAND ISLAND, NE
ZIP 68803
Phone: (308) 384-9505
Fax: (308) 384-4939

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. TAMARA LYNN BONNES-HEIL O.D., an active Optometrist specialist practicing in Grand Island, NE. Our medical registry currently tracks 3 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 47 documented patient claims. Among these therapy options, the most frequently utilized medication is Latanoprost, which accounts for 20 claims alone.

Medication Index

L
T
X
No matching medications currently found on file.

Latanoprost

Generic Formulation: LatanoprostSpecialty: Optometry
Provider Metrics Summary
Total Claims 20
30-Day Fills 27.8
Days Supply 781
NE State Average Benchmarks
Peer Average Claims121.0
Peer Average 30-Day Fills192.8
Peer Average Days Supply5,441
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 83.5% less volume than the regional standard for practitioners inside NE. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $280.92 across this reporting matrix range.

Provider Avg Cost Per Claim

$14.05

State Avg Cost Per Claim

$19.95

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A prostaglandin F analog used to treat OCULAR HYPERTENSION in patients with GLAUCOMA.

Therapeutic Applications

Latanoprost is used to treat high pressure inside the eye due to glaucoma (open angle type) or other eye diseases (such as ocular hypertension). It is similar to a natural chemical in the body (prostaglandin) and works by regulating the flow of fluid within the eye which results in lower pressure. Lowering high pressure inside the eye helps to prevent blindness.

Tobramycin-Dexamethasone

Generic Formulation: Tobramycin/DexamethasoneSpecialty: Optometry
Provider Metrics Summary
Total Claims 14
30-Day Fills 14.0
Days Supply 220
NE State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills23.3
Peer Average Days Supply315
Conservative Utilization

This provider writes prescriptions for this formulation 36.4% less frequently than the standard regional baseline metric for practitioners inside NE. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $679.78 across this reporting matrix range.

Provider Avg Cost Per Claim

$48.56

State Avg Cost Per Claim

$76.32

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A topical preparation of tobramycin and dexamethasone that is used for treating or preventing superficial bacterial infections of the eye.

Therapeutic Applications

This medication is used to treat or prevent eye infections. This medication contains two drugs. Tobramycin belongs to a class of drugs called aminoglycoside antibiotics. It works by stopping the growth of bacteria. Dexamethasone belongs to a class of drugs called corticosteroids. It works by reducing swelling. This medication treats/prevents only bacterial eye infections. It will not work for other types of eye infections. Unnecessary use or overuse of any antibiotic can lead to its decreased effectiveness.

Xiidra

Generic Formulation: LifitegrastSpecialty: Optometry
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 390
NE State Average Benchmarks
Peer Average Claims20.0
Peer Average 30-Day Fills25.9
Peer Average Days Supply769
Conservative Utilization

This provider writes prescriptions for this formulation 35.0% less frequently than the standard regional baseline metric for practitioners inside NE. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $9,864.74 across this reporting matrix range.

Provider Avg Cost Per Claim

$758.83

State Avg Cost Per Claim

$857.51

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat dry eye disease.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. TAMARA LYNN BONNES-HEIL O.D. provides transparency into local medical care patterns within Grand Island, NE.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Optometrist** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.